SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

Decoding the Israeli miracle: Can startup DNA be replicated?

When a WhatsApp message is worth a penthouse: Judges weigh digital vs. written promises

CISOs to pour 2026 budgets into AI as cybersecurity priorities shift

“Basic AI capabilities have become a commodity, so the most significant opportunity has shifted toward Vertical AI”

Buzz

Most popular

Daily

Weekly

1

Israel signs $130 million deal with Elbit to outfit next-generation helicopters

2

IBM invests in Israeli startup Anima to bring “vibe coding” into the enterprise

3

Ilya Sutskever’s Safe Superintelligence engineer walks away to fix what AI breaks

4

Fundamental exits stealth as $1.2 billion unicorn, armed with $255 million for tabular AI

5

Israeli startup raises $6.2 million to turn social media video into intelligence

Gilead

6 stories about Gilead

מנכ"לית קומפיוג'ן ד"ר ענת כהן דייג

Compugen shares soar on massive deal with Gilead, worth up to $848 million

19.12.23|Sophie Shulman

The Israeli company utilizes its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing novel cancer immunotherapies

פרופסור זליג אשחר

Scientist’s Ex-Wife Joins Legal Melee Over Kite Pharma Windfall

16.01.18|Zohar Shahar Levy

Zelig Eshhar, the patent holder for Kite Pharma’s anti-cancer technology, is currently being sued by a former student for infringement of patent rights

ההכרזה של דולנד טראמפ על ירושלים 2

CTech’s Daily Israeli Tech News Roundup

Backlash against Trump’s Jerusalem declaration has reached Israeli tech. AmTrust is planning a listing on Tel Aviv Stock Exchange. Teva’s stock is up following news of more layoffs.

Generic Focus made Kite Pharma Founder Leave Teva

13.11.17|Dror Reich

Founder of cancer treatment company sold to Gilead Sciences for $12 billion, says Gilead wants “to crack the cancer market"

Meet Kite Pharma's CEO, the Man Bringing Hope to Hodgkin's Lymphoma Patients

30.08.17|Dror Reich

With two exits worth hundreds of millions of dollars to his name even before selling Kite Pharma for $12 billion dollars, just where will Arie Belldegrun aim next?

Gilead To Buy Kite Pharma for $11.9 Billion

29.08.17|Dror Reich

The drug company is looking to diversify into cell therapy following declining hepatitis c drug sales